We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Department of Justice (DOJ) said yesterday it will not stand in the way of pharmaceutical companies sharing information on the manufacturing of monoclonal antibodies for the treatment of COVID-19 patients. Read More
Dynavax has partnered with Taiwan-based Medigen Vaccine Biologics to develop a COVID-19 vaccine candidate. The partners will evaluate Medigen’s recombinant form of the SARS-CoV2 spike protein combined with Dynavax’s CpG1018 adjuvant. Read More
Since February, the FDA has approved 361 generic drug applications and okayed nearly 300 manufacturing changes to help speed drugs to market for COVID-19 patients, FDA Commissioner Stephen Hahn said this week. He was touting the agency’s prompt response to the pandemic even though the agency’s numbers don’t back up that claim. Read More
Pfizer confirmed that it plans to charge $19.50 per dose of its COVID-19 vaccine in the U.S., with a total cost of about $40 for a two-dose regimen. Read More
HHS and the Department of Defense have signed their largest deal to date under Operation Warp Speed — a $1.95 billion contract with Pfizer and BioNTech for large-scale production and nationwide delivery of 100 million doses of their COVID-19 vaccine. Read More
Among other questions, the lawmakers asked what resources the agencies are using to assess the extent of the scams and what actions they are taking against those involved. Read More